Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Study of Fully Human Anti-GPRC5D Chimeric Antigen Receptor T Cells (CAR-GPRC5D) in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

NCT05759793 is registered in ClinicalTrials.gov with Nanjing IASO Biotechnology Co., Ltd. as lead sponsor.

NCT NCT05759793
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05759793 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Study of Fully Human Anti-GPRC5D Chimeric Antigen Receptor T Cells (CAR-GPRC5D) in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Lead sponsor
Nanjing IASO Biotechnology Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
March 30, 2023
Completion date
October 1, 2026
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

plasma cell leukemia, relapsed/refractory multiple myeloma